Despite being hounded by multiple controversies, vaccine maker Pfizer pushed through with clinical trial for its mRNA flu vaccine. The new shot utilizes the mRNA technology that can be found in the Wuhan coronavirus (COVID-19) shot.
A press release by the New York-based Big Pharma firm said the clinical trial will "evaluate the efficacy, safety, tolerability and immunogenicity of the firm's quadrivalent modified RNA influenza vaccine candidate in approximately 25,000 healthy U.S. adults."
Dr. Annaliesa Anderson, Pfizer senior vice president and head of vaccine research and development, said the company gained "an even deeper understanding of the opportunity to potentially provide more efficacious vaccines" thanks to its "experience with RNA viruses and mRNA technology" with the COVID-19 vaccines.
"We are excited to start the first Phase 3 efficacy study of an mRNA-based influenza vaccine that could potentially deliver an improved flu vaccine to help address the significant burden of this disease," she further stated.
The most recent venture of Pfizer raised more eyebrows as the company is still on the hot seat for controversies surrounding its COVID-19 vaccines, which used the same mRNA technology.
A lot of healthy people, even prominent ones, died suddenly after taking the mRNA vaccines. There are also publicly reported adverse effects that include altered menstrual cycles in women, lowered sperm count in men and cardiovascular issues in children and young adults. Trace amounts of COVID-19 vaccines have also been detected in breast milk.
Myriad of studies have already proven that vaccines harm adults, adolescents and young ones. Also, the true efficacy of the COVID jabs is questioned as several studies have demonstrated that natural immunity is superior to COVID-19 vaccination and that the recommended booster regimen may not protect recipients as strongly as promised.
Even Dr. Robert Malone, the inventor of mRNA vaccine technology, has repeatedly criticized Pfizer's COVID-19 shots.
Pfizer CEO catches COVID-19, backs out of planned testimony
Meanwhile, Pfizer CEO Albert Bourla announced that he tested positive for COVID-19 for the second time in six weeks. While he claimed in 2021 that his company's vaccine was 100 percent effective in preventing COVID-19, it appeared that even four doses of the shot failed to protect him.
The Big Pharma executive posted on Twitter that he was feeling well and symptom-free. "I was following guidelines to wait three months since my previous COVID-19 case, which was back in August," he tweeted. "While we've made great progress, the virus is still with us."
Because of this infection, Bourla pulled out of his planned Oct. 10 testimony before the European Parliament's Special Committee on the COVID-19 Pandemic. The Pfizer CEO confirmed his illness 15 days before his appearance. (Related: Pfizer CEO backs out of testifying at EU Parliament after reports of backdoor dealings with European Commission president.)
Even though Bourla did not show up, the committee has questioned several pharmaceutical industry bigwigs. These include Moderna CEO Stephane Bancel and senior officials from AstraZeneca and Sanofi.
The European Court of Auditors reported that European Commission President Ursula von der Leyen had been directly involved in preliminary negotiations for the biggest vaccine contract – up to 1.8 billion doses of the BioNTech/Pfizer vaccine – which was concluded in May 2021. In 2021, the New York Times reported on the seemingly cozy relationship between Bourla and von der Leyen, with the two exchanging text messages in the run-up to the deal.
Visit BigPharmaNews.com for more news about Pfizer and other vaccine makers.
Watch the below video that discusses why Bourla backed out of testifying before the European Parliament regarding the vaccine deals.
This video is from the What is happening channel on Brighteon.com.
More related stories:
Pfizer DID NOT test its COVID-19 vaccine for possible effects on male fertility.
Ben Armstrong: Pfizer knows the COVID vaccine is dangerous for pregnant women.
Sources include:
Please contact us for more information.